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Abstract  1 
Spectroscopy techniques are valuable tools in biomedical research and have been used 2 
extensively in the study of disease. However, neurological conditions such as multiple 3 
sclerosis (MS) have received little attention and the available spectroscopy studies are 4 
limited, both in overall numbers of patients studied and the disease samples considered. MS 5 
is a complex immune-mediated disease, with variable clinical courses and limited 6 
therapeutic options. This review aims to summarize current literature in the area, 7 
demonstrating how spectroscopy techniques can provide valuable information to inform and 8 




Biophotonic techniques are now widely used in biomedical research targeting better 11 
diagnosis, prognosis and surveillance of disease.  Vibrational spectroscopy methods such as 12 
Fourier-transform infrared (FTIR) and Raman spectroscopy are so called because they 13 
probe the intramolecular vibrations and rotations of a sample when irradiated with a light 14 
source (1). The vibrational energy levels can be probed by both techniques, using different 15 
physical processes. Raman spectroscopy studies the Raman effect, the spontaneous 16 
inelastic light scattering process of photons, following the interaction of monochromatic 17 
radiation (e.g. a laser) with the sample. In contrast, FTIR spectroscopy studies the samples’ 18 
absorption characteristics arising from the molecular motion due to atomic displacement 19 
upon interaction with an infrared source (2, 3). In both cases, the recording of vibrational 20 
energy level transactions results in a spectrum composed of peaks/bands that can be 21 
interpreted qualitatively (peak position) and quantitatively (peak intensity/area) (4). In FTIR 22 
spectroscopy, the spectral bands arise from a change in the electric dipole moment of the 23 
molecules, whereas in Raman spectroscopy, they arise from a change in molecular 24 
polarizability. FTIR and Raman spectroscopies are therefore complementary and provide a 25 
"fingerprint" or "signature" of the specific molecules contained within a biological sample 26 
(proteins, lipids, DNA), depending upon whether their bonds exhibit infrared or Raman 27 
activities. Both FTIR and Raman can be used for imaging tissue sections and are non-28 
destructive, label-free techniques with sub-micron spatial resolution (5).  29 
In biomedical research, scientists are continually investigating and exploring the application 30 
of new technologies that can detect early signs of disease and thereby reduce disease 31 
morbidity and mortality. The detection of biomarkers plays an important role in this 32 
exploration. In oncology, such biomarkers, have been used extensively to determine risk 33 
factors, aid diagnosis and prognosis, and in the assessment of treatment response as well 34 
as determining disease recurrence (4). However, from amongst the vast numbers of 35 
candidate biomarkers, only a limited few have been validated for clinical use. Vibrational 36 
spectroscopy is new investigatory tool in biomarker (re)search which is not restricted to the 37 
analysis of a specific protein, nucleic acid and/or lipid. As such, FTIR and Raman spectra 38 
are able to give spectral "signatures" or "biomarkers" which reflect the overall molecular 39 
composition of the studied samples (4).  40 
Despite being extensively used in the field of cancer research (6, 7), FTIR and Raman 41 
spectroscopy are currently under explored in the study of diseases which affect the central 42 
nervous system (CNS) including multiple sclerosis (MS). To date, there are very few 43 
published papers in this field including a review article published in 2012 (8).  44 
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Multiple Sclerosis (MS) 45 
MS is considered to be an autoimmune, neuro-inflammatory and degenerative condition, 46 
which affects both the brain and spinal cord. Its precise aetiology remains unknown, 47 
although both genetic and environmental factors influence an individual's susceptibility to 48 
develop MS (9). The clinical course of this disease is variable but is divided into several 49 
categories reflecting the degree of clinical disease activity and disability progression rate, 50 
including relapsing remitting (RRMS), primary progressive (PPMS) and secondary 51 
progressive MS (SPMS) (10). Whilst the inflammatory component of MS pathogenesis is 52 
relatively well understood, the progressive neurodegenerative component of the disease, in 53 
both its primary and secondary progressive clinical courses, is yet to be elucidated. In 54 
PPMS, patients have a gradual and progressive decline in function from the outset, with 55 
minimal disease activity detectable on magnetic resonance imaging (MRI) whereas in 56 
SPMS, the gradual progression follows an initial relapsing remitting phase, usually over 57 
many years (11). The consensus is that MS is a spectrum of conditions with RRMS being 58 
one end of that spectrum and PPMS being at the other.  59 
The key pathological features observed in MS are the influx of inflammatory immune cells 60 
across the blood brain barrier into the CNS which results in the loss of axons and their 61 
insulating myelin sheaths and the formation of lesions (plaques) in the white matter (WM) 62 
and to a lesser extent in the grey matter (12). This process results in the impairment of 63 
conduction along the affected axon leading to variable symptoms experienced by affected 64 
patients including cognitive impairment, visual disturbances, sensory and motor symptoms, 65 
impaired balance, sphincter disturbance and fatigue (13). Histopathological comparisons of 66 
CNS tissue shows that the classical perivascular inflammation seen in SPMS is much less 67 
prominent in PPMS and that more diffuse inflammatory changes and greater extent of 68 
axonal damage in the normal appearing white matter (NAWM) are seen in PPMS (14, 15). In 69 
addition, there is evidence that patients with PPMS have a reduced capacity for re-70 
myelination (11). Understanding the underlying pathogenesis which underpins the clinical 71 
progression in MS at the molecular and cellular levels is therefore vital for the development 72 
of therapies targeting the neurodegenerative process and enhancing remyelination 73 
strategies.  74 
The diagnosis of MS is usually based on the clinical presentation and the results of brain and 75 
spinal MRI, which reveals evidence of active and chronic lesions as well as focal and 76 
generalised atrophy (16). Current treatments for MS target the initial relapsing phase of the 77 
disease, by preventing inflammatory responses leading to a reduction in the number and 78 
severity of relapses (17). However, there are currently no treatments for primary and 79 
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secondary progressive MS although two therapeutic agents are waiting to be licenced (18). . 80 
The underlying pathogenesis of the initial inflammatory phase of MS has been well 81 
characterised at both the cellular and molecular level. However the pathogenesis of the 82 
progressive phase is still not fully elucidated,  although changes in the NAWM appear to be 83 
pivotal (12). The progressive loss of axons seem to continues despite the reduction of 84 
relapses with the use of effective anti-inflammatory therapies resulting in irreversible 85 
disability which support the presence of two separate pathological processes: inflammation 86 
and neurodegeneration (19). 87 
Approaches to studying MS pathogenesis have focussed on the analysis of post-mortem 88 
CNS tissue, as well as experimental work using both primary CNS cells such as astrocytes, 89 
microglia and oligodendrocytes isolated from CNS tissue, which allows manipulation of the 90 
individual cell's environment.  In addition, a number of animal models of MS have been 91 
developed, primarily in rodents but also in primates, in order to investigate the disease 92 
course of MS. In these animals, experimental autoimmune encephalomyelitis (EAE) is  93 
induced through the injection of spinal cord homogenates, myelin proteins or peptides, such 94 
as myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP) or proteolipid 95 
protein (PLP), in addition to adjuvant. This promotes the induction of an autoimmune 96 
response against myelin, leading to both an inflammatory response in the CNS as well as, 97 
dependent on the model used, demyelination (20). Nevertheless, the progressive aspects of 98 
the human condition seen in MS are more difficult to reproduce in animal models (21), 99 
although Peferoen has recently described an EAE model in Biozzi mice which, dependent on 100 
the age of the mouse at induction of disease, demonstrates progressive disease, with 101 
younger mice having an initial relapsing remitting phase followed by a secondary 102 
progressive phase and older mice showing progression at onset of disease induction (22). A 103 
further drawback of these animal models is that off the multitude of therapies found to be 104 
effective in preventing EAE, a very small number have been taken forward into clinical trials 105 
(23), suggesting that the models do not fully mimic the pathogenesis of MS in humans. 106 
Current research approaches to investigating the aetiology of MS focus on the search for 107 
specific genes/proteins/lipids that are thought to be involved in the disease process using a 108 
variety of cell and molecular biology approaches. More recently DNA microarrays have been 109 
used to assess more global changes in gene expression in MS diseased human CNS tissue 110 
compared with normal age matched control (24, 25). The application of proteomic and 111 
metabolomic analyses in MS have focussed on biomarkers in biological fluids, including 112 
blood, cerebrospinal fluid and urine rather than in MS CNS tissue (26, 27). 113 
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The advantage of Raman and FTIR for analysis of human tissues is that the overall chemical 114 
composition of the tissue in terms of lipids, nucleic acids and proteins is obtained. 115 
Spectroscopic study of MS has been reported in the literature using both human post-116 
mortem CNS tissue and animal models of the disease. A review of all available original 117 
research articles published to date is provided below and is summarized in Table 1.  118 
 119 
Human CNS tissue spectroscopy studies 120 
Initial studies applying spectroscopic techniques to the study of MS pathology were reported 121 
in the 1990s. Choo et al. were the first to use FTIR to study human white and grey matter 122 
tissue, obtained from healthy control subjects, and compared it with MS demyelinated 123 
lesions tissue from MS patients (28). This rapid communication reported that it was possible 124 
to discriminate between different types of MS tissue attributed to variations in intrinsic lipid 125 
and water content. Whilst FTIR spectra of white matter was dominated by lipids and protein 126 
absorptions and grey matter spectra showed reduced lipid content alongside an increase 127 
contribution of water to the spectra; MS lesion spectra were suggestive of both lipid and 128 
water depletion, as would be expected from histopathological tissue analysis (28).  129 
Differences comparing white and grey matter as well as white matter with MS lesions were 130 
most notable in the 2800-3000 cm-1 spectral region, where most infrared bands arise from 131 
CH2 and CH3 stretching vibrations of lipid acyl chains. Four main assignments were made to 132 
CH3 and CH2 asymmetric stretching vibrations at 2956 and 2922 cm-1 and, to symmetric 133 
vibrations at 2871 and 2851 cm-1 respectively. The overall intensity of these peaks were 134 
reduced in both grey matter and MS lesion tissue, compared to normal control white matter, 135 
which the authors explained was due to the expected lower lipid content of grey matter and 136 
MS lesions, due to demyelination. Similarly, the CH2/CH3 ratio is also decreased as a 137 
decrease in lipid to protein ratio leads to methylene and methyl groups of amino-acid side 138 
chains dominating this spectral region; as the CH2/CH3 ratio in proteins is much lower than in 139 
lipids, it was expected that the overall ratio would be decreased and band broadening would 140 
be observed. In order to distinguish between grey matter and MS lesion tissue, the authors 141 
reported the spectral region of 1200-1800 cm-1 to be most useful (28).   142 
The main feature in white matter' spectra was observed at 1467 cm-1 and assigned to the 143 
scissoring vibration of CH2 groups of lipid acyl chains. In grey matter, the intensity absorption 144 
of this CH2 scissoring is reduced and is almost equal to the CH3 asymmetric bending 145 
vibrations at 1456 cm-1. This is explained by the reduction in lipid content, which is also 146 
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apparent by the decrease in intensity of the terminal methyl groups of lipid chains and of the 147 
(CH3)3N+ symmetric bending of phosphatidylcholine headgroups, assigned to the bands at 148 
1381 and 1415 cm-1, respectively. In contrast the COO- symmetric stretching band at 1400 149 
cm-1 is increased in the spectra of grey matter in comparison to white matter. The same was 150 
also observed at 1308 cm-1 which the authors assigned to amide III(28).  151 
The spectral features of MS plaque tissue are similar to the ones described for grey matter. 152 
Nevertheless, the intensity of CH2 scissoring (1467 cm-1) to CH3 asymmetric bending 153 
vibrations (1456 cm-1) is now reversed with CH3 asymmetric bending vibrations being the 154 
main feature in this region. Similarly, the PO2- antisymmetric stretching band also displays 155 
greater intensity in the plaques' spectra comparatively to grey matter. Both these 156 
observations were suggested to indicate that lipid content of MS plaques is lower than that of 157 
the grey matter (28), which is known to be the case from histopathology studies (13). 158 
In the 1500 to 11800 cm-1 spectral range the main feature observed was the amide I band 159 
which arises from the C=O stretching vibration of amide groups of proteins and is centred at 160 
1653 cm-1. Other absorptions reported were assigned to C-C stretching of tyrosine at 1517 161 
cm-1; the amide II band centred at 1550 cm-1; and the acidic amino-acid and arginine side 162 
chains at 1581 and 1580-1610 cm-1 respectively. In addition, the ratio of amide I to amide II 163 
was increased comparatively to that of isolated proteins. It was suggested this may result 164 
from non-protein contributions to the amide I region, and further proposing water to be the 165 
main source of this contribution (28).  166 
Le Vine et al. (1998) assessed active lesions in MS tissue compared with healthy control 167 
white matter and reported an increased oxidation state of both lipids and proteins in MS 168 
lesions, indicative of a role for free radicals in MS pathogenesis (29).  The spectra of WM 169 
tissue from control post-mortem cases was dominated by CH2 absorptions at 2923 and 1468 170 
cm-1, P=O at 1235 cm-1 and HO-C-H at 1060 cm-1, characteristic of lipids, phospholipids and 171 
glycolipids respectively. Areas of NAWM within MS cases were reported to display similar 172 
spectra to normal control white matter, whereas lesion areas display significant changes, 173 
such as a reduced ratio of CH2 to NH and OH, in comparison with control white matter. 174 
Further differences were revealed by the investigation of the oxidation products of lipids and 175 
proteins. Previous studies reported the amide I peak at ~1660 cm-1 to be broader when 176 
proteins are oxidised and the carbonyl absorption at 1740 cm-1 to be increased when lipids 177 
are oxidised. This study reported the C=O (1740 cm-1) to CH2 (1468 cm-1) ratio to be 178 
increased and the peak at 1657 cm-1 to be broader in MS lesions in comparison with white 179 
matter from control samples (29). 180 
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Furthermore, the authors followed the spatial spectroscopic profiles of these features by 181 
recording linear maps acquired partially or wholly within MS lesions sites and representative 182 
areas of control white matter. They reported the CH2 (1468 cm-1) to amide II (1544 cm-1) ratio 183 
to be 0.644±0.053 for control samples (n=5), ranging from less than 0.1 to 0.7 in MS ones 184 
(n=5); 15.950±1.593 was the mean of the C=O (1740 cm-1) to amide II (1544 cm-1) ratio in 185 
control cases, which was in turn decreased for all MS cases; and four out of five MS cases 186 
presented one or more values above the mean of 24.047±3.22 for C=O (1740 cm-1) to CH2 187 
(1468 cm-1) ratio of control samples. Finally, whilst controls displayed an average of -188 
0.033±0.010 at 1652 cm-1, MS cases displayed greater values all above -0.02 (29). 189 
It was concluded that the higher carbonyl to CH2 ratio detected in the spectra of MS cases is 190 
suggestive of lipids being oxidised, whilst oxidation of proteins cause the 1657 cm-1 peak to 191 
broaden to 1652 cm-1 in MS plaque tissue. This result may be caused by gliosis, which 192 
occurs in parallel with the demyelination process leading to higher expression of glial 193 
fibrillary acidic protein by astrocytes, which was also indicated as a potential factor 194 
contributing to the amide I broadening, as well as the relative greater expression of amide II 195 
(29). 196 
More recently, Poon et al. used Coherent Anti-Stokes Raman Scattering (CARS) to study 197 
several regions of post-mortem MS brain, including areas of NAWM, remyelination and both 198 
active and chronic lesions (30). Investigating five chronic MS cases, they reported a novel 199 
instrument that allows acquisition of high resolution, label-free imaging whose pixels contain 200 
spectral information, together with a post-processing method, which allows isolation and 201 
quantification of these spectral images. The study showed the CH2 symmetric stretch of 202 
2850 cm-1 in NAWM, to shift to 2885 cm-1 when myelin was contained within the phagocytic 203 
macrophages/microglia cells within the tissue (a CARS image is overlaid with 204 
immunostaining with the marker HLA-DR/LN3, confirming activated microglia). This was 205 
proposed to arise from the intermolecular chain disorder resulting from the breakdown of the 206 
myelin components during demyelination. Further CARS pseudo-colour images showed 207 
myelinated axons to have greatly reduced density within remyelinated areas in active lesion 208 
sites (30). 209 
 An additional study, also by Poon et al. reported lipid biochemical changes preceding myelin 210 
protein loss in peri-lesional areas and NAWM, when inspecting the CH spectral region from 211 
2750 to 3100 cm-1 (31). CARS images were acquired from the NAWM region adjacent to the 212 
lesion and sequential images were acquired moving away from the lesion into the NAWM.. 213 
Triplicate images were also acquired from an area furthest away from the lesion site, 214 
referred to as "true NAWM" and from matched brain regions in tissue sections from control 215 
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non-MS cases. The average "true NAWM" spectra did not overlap with region-matched 216 
control spectra, suggesting possible underlying pathology in MS tissue, which is not 217 
differentiated when using lipophilic histochemistry or immunostaining with conventional 218 
techniques (31).  219 
The three major features in the CH spectral region analysed, correspond to the symmetric 220 
and asymmetric and asymmetric stretching of acyl chain methylene at 2850 and 2886 cm-1 221 
respectively, and the CH3 methyl chain end symmetric stretch at 2935 cm-1, which is thought 222 
to include protein contributions as well. Observing the intensity ratios of 2850/2880 cm-1 and 223 
2935/2880 cm-1 the authors noted a slowing decreasing trend across all measured intensity 224 
ratios, when moving away from the lesion site until reaching the "true NAWM" ratios, 225 
recorded from an area the furthest away from the lesion, and approaching the ratios of 226 
region-matched non-MS control samples. The 2850/2880 cm-1 ratio is thought to relate to the 227 
intermolecular packing, interchain interactions and intrachain torsional motions, whereas the 228 
2935/2880 cm-1 ratio allows monitoring intramolecular chain disorder and trans-gauche 229 
isomerisation. The authors conclude that biochemistry of myelin lipid content changes in the 230 
lesion periphery and in NAWM (31). 231 
Mouse models of demyelination and remyelination 232 
Animal models of MS have also been investigated by vibrational spectroscopy, where most 233 
studies aim to elucidate the mechanisms behind demyelination and remyelination. Heraud et 234 
al. used FTIR spectroscopy to investigate macromolecular components and protein 235 
conformational changes in the CNS of EAE versus control tissue sections(32). Using 236 
principal component analysis (PCA) and artificial neuronal networks (ANN) to analyse single 237 
data acquisition spectra, the authors demonstrated, without the need for chemical stains, 238 
subtle chemical and structural changes, particularly in the secondary structure of proteins in 239 
the white matter (33).  240 
Fu et al. used resonant CARS imaging from the symmetric CH2 stretch vibration at 2840 cm-241 
1
 to characterize myelin changes induced by lysophosphatidyl choline (lyso-PtCho) (34). 242 
Although not directly relevant to demyelinating diseases including MS, the authors reported 243 
CARS was able to characterise the changes occurring in lyso-PtdCho-induced myelin 244 
breakdown and that together with electrophysiological data, it revealed involvement of a 245 
Ca2+, calpain, and cPLA2-dependent pathway (34). 246 
In another study, CARS was used to study myelin loss in the mouse-model, Relapsing-EAE 247 
(R-EAE) (35). Two theories have been hypothesised for initiating demyelination, one where 248 
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the injury starts at internodal myelin, thinning layer by layer and the other, where it initiates 249 
with paranodal domain injury.  The authors noted that the submicron spatial resolution of 250 
CARS images allowed not only the quantification of myelin thickness but also the ratio of 251 
myelin thickness to the axonal diameter at different stages of the disease process. 252 
Furthermore, two-photon immunofluorescence microscopy revealed that juxtaparanodal K+ 253 
channels, paranodal myelin retraction and the displacement of K+ channels was extensively 254 
observed at the onset of R-EAE and at lesion borders. Overall their results suggested loss of 255 
nodal integrity precedes the formation of myelin debris in the CD4+ T-cell-mediated R-EAE 256 
model of MS and that remyelination is accompanied by reestablishment of the nodal makers, 257 
with myelin being only partially restored (35). 258 
Furthermore, the Raman spectra of myelin were dominated by lipid assignments and the 259 
authors studied both C-C and C-H vibrational bands to determine the conformation of their 260 
hydrocarbon chains through: (1) lipid packing studied using prominent bands at 2850, 2885 261 
and 2930 cm-1, assigned respectively to stretching and asymmetric stretching of CH2 and to 262 
CH3 stretching: and, (2) lipid unsaturation using the I1650/I1445 ratio, which represents the 263 
C=C stretching bands to H-C-H deformation bands in lipid acyl chains. Myelin debris 264 
presented a higher intensity of the I2930/I2885 ratio, reflecting an increased intermolecular 265 
chain disorder; and regenerated myelin presented a higher lipid-packing disorder than 266 
normal myelin. Similarly, myelin debris presented the highest unsaturation degree, which 267 
was decreased in regenerated myelin but nevertheless was higher than normal myelin. 268 
Finally, the analysis of the I1122/I1076 ratio, revealed no significant change could be 269 
observed in the intramolecular chain ordering of myelin debris, normal and regenerated 270 
myelin (35). 271 
A non-invasive multimodal CARS system, combining reflectance for visualizing axons, 272 
fluorescence to visualize green fluorescence protein (GFP) and Raman to visualize myelin 273 
and to monitor microglia induced neurodegeneration was reported by Imitola et al. (36).  274 
Using an EAE model, the authors reported fast ex vivo imaging of myelin, axons and 275 
microglia with great anatomical precision in live tissue. CARS images showed a global 276 
decrease in myelination, not seen before through other imaging techniques. This suggests 277 
that subtle alterations in the myelin lipid content may precede hallmark CNS demyelination, 278 
which is correlated with axonal loss and microglia activation (36).   279 
Wang et al. reported DBT (3,3'-diethylthiatricarbocyanine iodide) to be a promising probe for 280 
Near Infrared Fluorescence (NIRF) imaging of myelination (37). Through in vivo NIRF 281 
studies on hyper and hypomyelination mouse models, the authors demonstrated DBT 282 
successfully enters the brain and selectively binds to myelin sheaths. Furthermore, aiming to 283 
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broaden NIRF-DBT imaging to MS disease, the authors studied a cuprizone-induced mouse 284 
model for demyelination and remyelination. NIRF imaging and quantitative analysis revealed 285 
DBT could successfully monitor the level of demyelination and subsequent remyelination in 286 
this mouse model, that could be correlated with histochemical staining (37). 287 
Future research directions 288 
The current literature, as reviewed above, considering human post-mortem CNS tissue 289 
specimens is limited, with most studies considering a nominal sample number as shown in 290 
Table 1, which also summarises the studies completed in models of MS.   291 
Studies focusing on animal models have shown spectroscopy to be a valuable tool in 292 
probing the biochemical composition of samples otherwise deemed identical. The spectral 293 
imaging of myelinating and remyelinating processes, for example, further demonstrated the 294 
ability to differentiate between newly formed myelin and endogenous myelin, indicating the 295 
remyelinating process generates myelin of a different composition.  Nonetheless, studies 296 
considering human samples are limited and concern only a small number of post-mortem 297 
tissues as human CNS material is difficult to obtain. Furthermore, most studies focused on 298 
the spectral distinction of MS lesions from control tissue of non-diseased subjects, which can 299 
readily be achieved by macro and microscopic evaluation using luxol-fast blue (LFB) stain or 300 
immunohistochemistry for myelin proteins to examine demyelination. As disease diagnosis 301 
through tissue sampling is not feasible, the advantages of spectroscopy techniques such as 302 
FTIR and Raman rely on their ability to reveal underlying biochemical changes not yet 303 
detectable either macro or microscopically, for example on NAWM of MS cases, when 304 
common techniques fail to recognize differences. Spectral data could potentially help to 305 
understand the underpinning mechanisms of disease and advance research in the field by 306 
probing deeper into the chemical composition of apparently normal areas of MS cases.  307 
FTIR and Raman spectroscopy analysis of post-mortem white matter MS tissue: 308 
NAWM has a different signature 309 
Analysing four post-mortem brain samples obtained from UK MS Society Tissue Bank 310 
(Imperial College London) we show FTIR signatures allow the distinction of normal control 311 
WM from both active and chronic lesions, and more interestingly from the NAWM of MS 312 
cases despite no visible demyelination being observed when staining NAWM with LFB.  The 313 
mean FTIR spectra of a brain tissue sample from control, NAWM, active lesion and a chronic 314 
lesion are represented in Figure 1, where it is possible to observe that the symmetric and 315 
anti- symmetric C-H stretches attributed to lipids ~2800-3000 cm-1 gradually decrease from 316 
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control to active lesion, as do the C-O and P-O stretches attributed to nucleic acids after 317 
1000 cm-1. 318 
This decrease in lipid content seems to be in line with the previous findings acknowledged in 319 
this review of published work and is in agreement with the well characterised process of 320 
demyelination which occurs in MS, providing support to the validity of this approach to the 321 
study of the biochemical composition of brain tissue in MS. 322 
Principal Component Analysis (PCA) was further employed to highlight the variability existing 323 
in the recorded spectral data set. PCA of FTIR signatures allowed the distinction of normal 324 
control WM from both active and chronic lesions, as expected, but also differentiated NAWM 325 
of the MS cases from control white matter cases. 2-D PCA scatterplot is shown in Figure 2.  326 
A clear distinction between all sample groups can be observed. If the distinction between 327 
control and chronic and active lesions were expected due to MS pathology, the separation 328 
between NAWM and control WM provides novel insights into the alterations in white matter 329 
in MS which might contribute to disease progression.  330 
PCA was also employed to compare FTIR data from NAWM and control white matter 331 
samples and results are shown in Figure 3.  Figure 3A indicates that NAWM and control 332 
white matter FTIR spectra separate according to the 1st principal component (PC1) which 333 
accounts for 80.63% of the variation observed within the data set. The PC1 loading 334 
represented in Figure 3B shows that this separation is dominated by the negative loading of 335 
two main lipid assignments ~2800-3000cm-1 indicating these are more intense in the control 336 
WM samples (in black on the negative part of the PCA plot (Figure 3A)).  337 
These preliminary results demonstrate that FTIR spectroscopy can be applied to analysis of 338 
post-mortem WM tissue and successfully discriminate not only between lesion and control 339 
WM but also between NAWM and control, without requiring any additional techniques. 340 
Furthermore, they are suggestive of a significant decrease in lipid content in NAWM tissue in 341 
MS cases, which is not detected by current staining techniques or documented in the 342 
literature, but ought to be further investigated to better understand MS pathogenesis and the 343 
biochemical changes that lead to lesion formation. Finally, the spectral signatures of the 344 
fingerprint region also pointed to additional differences at the protein and nucleic acid level; 345 
these pose further questions as to which specific species (i.e. proteins) are being ‘lost’ in 346 
NAWM samples, which could contribute to the disease process.  347 
Similarly, the samples were also analysed using a Horiba XploRA PLUS confocal Raman 348 
microscope, operating with 532nm laser light and 1800nm lines grating. Raman signatures 349 
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of the fingerprint region were analysed using PCA and results are shown in Figure 4. PCA 350 
score plots, in Figure 4A, showed the separation of NAWM (black) and control WM (green) 351 
only to be achieved on the third PC which account for approximately 2% of the variance 352 
found within the dataset. PC 1 and 3 loadings are shown in Figure 4B.  Our group is 353 
currently investigating the Raman signatures of NAWM samples further and a full research 354 
paper will be published in due course.  355 
FTIR and Raman spectroscopy analysis of biofluids  356 
Much like tissues, biofluids exhibit vibrational spectra that have characteristic bands 357 
reflecting their bimolecular composition (4). There are several reports of the application of 358 
Raman and FTIR spectroscopy to the study of body fluids. Although blood and serum are 359 
most commonly used due to their easy, less-invasive availability other biofluids including 360 
cerebrospinal fluid (CSF), bile, urine, saliva, pancreatic juice, synovial and pleural fluids, 361 
which are considered to more closely reflect ongoing pathology in the associated diseased 362 
tissue, have also been studied. In Alzheimer's disease, serum data from Raman 363 
spectroscopy allowed differentiation of Alzheimer's patients from other dementia cases (38), 364 
whereas in a different study, plasma spectral data was used to grade mild, moderate and 365 
severe Alzheimer's disease cases (39). FTIR spectroscopy showed Alzheimer's patients' 366 
plasma samples to be well delineated from normal ageing subjects (40) and the same was 367 
demonstrated for CSF (41). More recently, PCA-LDA allowed the distinction of the different 368 
types of mild, moderate and severe Alzheimer's disease cases and controls, with 85% 369 
accuracy, when using white blood cells from patients, using FTIR spectra and about 77% 370 
when using the plasma spectra. These 83% accuracy values increased to 83 and 89% when 371 
only moderate and severe patient groups were being considered (42). 372 
FTIR spectroscopy analysis of synovial fluid has been shown to allow differentiation of joints 373 
affected by rheumatoid arthritis, osteoarthritis, spondyloarthropathies and meniscal 374 
injuries(43); whereas a Raman study showed the ability to discriminate patients with low and 375 
high osteoarthritis severity (44). More recently, FTIR analysis of blood plasma for diagnosis 376 
of schizophrenia and bipolar disorders against a healthy control group has also been 377 
reported (45). A separation of all sample groups was observed using PCA, with assignments 378 
to lipids from lipoproteins, polypeptides, and phosphates associated to the DNA backbone 379 
being responsible for the separation; whilst PLS-DA allowed for the correct classification of 380 
all sample groups. Sensitivity and specificity results were highest when the full spectral 381 
range was considered, being respectively 100 and 100% for schizophrenia and 100 and 382 
84.6% for bipolar disorder. 383 
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Overall, as demonstrated in this review and from our own FTIR preliminary data, 384 
spectroscopic techniques have the potential to advance our knowledge of MS pathogenesis. 385 
The analysis of post-mortem material, especially the comparison between NAWM and 386 
normal WM can provide insights into molecular changes unveiling novel disease 387 
mechanisms. And, although currently it cannot be applied for diagnostic purposes, due to the 388 
constraints of obtaining brain tissue specimens, other patient specimen samples such as 389 
CSF and blood might prove useful in the future to achieve a more rapid and accurate 390 
diagnosis and prognosis for people with MS, much like has been recently reported for other 391 
CNS diseases such as Alzheimer’s.  392 
Conclusion  393 
The understanding of the underlying mechanism that lead to disease pathology and specially 394 
disease progression is of great importance in neurodegenerative conditions, such as MS. 395 
Spectroscopy techniques have the ability to unbiased characterisation of the biochemical 396 
composition of post-mortem and clinical samples alike, thus able of providing insights into 397 
the underlying changes occurring in tissue and biofluids (i.e. blood and CSF) which in turn 398 
could be helpful to guide future in vitro research aimed at novel therapeutics.  399 
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Table 1 Studies considered in this literature review. Sample specimen type and numbers 








Choo et al. 1993 Human 3 FTIR 
LeVine et al. 1998 Human 10 FTIR 
Fu et al. 2007 Mice - CARS 
Heraud et al. 2010 Mice 12 FTIR 
Belanger et al. 2011 Mice 14 CARS 
Shi et al. 2011 Guinea pigs - CARS 
Wang et al. 2011 Mice 7 NIRF 
Imitola et al. 2011 Mice - CARS 
Fu et al. 2011 Mice - CARS 
Begin et al. 2013 Mice 4 CARS 
Poon et al. 2013 Human 5 CARS 
Hu et al. 2014 Xenopus laevis - SRS 











Figure 1. Mean FTIR spectra for four post-mortem samples analysed in the preliminary 
study: chronic lesion (blue), active lesion (red), NAWM (green) and control (black). All 
samples were subjected to FTIR analysis at the Focas Research Institute, DIT, using a 
Perkin Elmer Spotlight 400N FTIR imaging system, incorporating a liquid nitrogen cooled 
mercury cadmium telluride 16x1, 6.25µm pixel array detector, and acquired by the Spectral 
Image software. FTIR images from the tissue sections (10µm sections) mounted on CaF2 
slides were recorded over the range 4000-800 cm-1 in transmittance mode with a resolution 
of 4 cm-1 and interferometer speed of 1.0 cm-1/second at continuously varying magnification. 
The scans per pixel for background were 120 and, for images, 16 per pixel respectively. 
Spectroscopic data analysis was carried out in Matlab, version R2013 (Mathworks, CA, 
USA) according to protocols developed and routinely used in-house at DIT. 
Figure 2. PCA of the four post-mortem samples FTIR data. (A) 2-D PCA scatterplot showing 
a separation between chronic (blue) and active lesion (red) and, NAWM (green) and control 
(black). (B) PC1 loading, responsible for the separation, is negatively dominated by peaks 
assigned to lipids around 2800-3000cm-1. 
Figure 3. PCA of the NAWM and control FTIR data. (A) The two dimensional PCA plot 
shows a separation between NAWM (black) and control (green) FTIR spectra in PC1 which 
explains 80.63% of the variation found in the data. (B) The PC1 loading is negatively 
dominated by peaks assigned to lipids around 2800-3000cm-1.  
Figure 4. PCA of the four post-mortem samples Raman spectroscopy data. (A) 2-D PCA 
scatterplots showing a separation between chronic (blue) and active lesion (red) and, NAWM 
(green) and control (black). (B) PC1 and PC3 loadings, responsible for the separation.  
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